Clemizole hydrochloride is under clinical development by EpyGenix Therapeutics and currently in Phase II for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy). According to GlobalData, Phase II drugs for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Clemizole hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Clemizole hydrochloride overview
Clemizole HCL (EPX-100) is under development for the treatment of Dravet syndrome, Lennox-Gastaut syndrome and otahara syndrome. The drug candidate acts by targeting 5-hydroxytryptamine receptor (serotonin receptor). The drug candidate administered orally. It is developed based on proprietary phenotype-based zebrafish drug screening platform.
For a complete picture of Clemizole hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.